Clinical Trials Browser

Phase 1/2 × Melanoma × sargramostim × Clear all

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Phase 1/2 Recruiting

Uveal Melanoma, Melanoma

NCT02275416 2024-12-16

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Phase 1/2 Completed

Melanoma

NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

Phase 1/2 Withdrawn

Melanoma, Skin Neoplasms

NCT00089219 2014-11-20

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Phase 1/2 Completed

Uveal Melanoma, Melanoma

NCT00002817 2014-01-10

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 1/2 Unknown

Melanoma

NCT00004184 2013-04-12

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 1/2 Completed

Melanoma